Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

Norwegian NOR study (remdesivir)
  NCT04321616		 RCTremdesivirstandard of careCOVID 19 all comerssome concern
43/58 no results
    Chang Chen et al.
          ChiCTR2000030254    		 RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
    		120/120 inconclusive
    • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    ELACOI (Standard of care)
          NCT04252885    		 RCTumifenovir (arbidol)standard of careCOVID 19 all comerssome concern
    		16/7 inconclusive
      Lou (FAVIPIRAVIR)
              ChiCTR2000029544      		 RCTfavipiravir standard of careCOVID 19 all comerssome concern
      		10/10 inconclusive
      • inconclusive 82 % decrease in viral clearance ,viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
      NCT04310228-FAVI (Zhao)
              ChiCTR2000030894      		 RCTfavipiravir tocilizumab COVID 19 all comerssome concern
      		-/- inconclusive
      • inconclusive 68 % decrease in radiologic improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      7 studies excluded by filtering options (3 RCT / 4 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons